Discovery & characterization
What the plant is, what it contains, what could be wrong.
Each page gives the science, its limits, the planned in-house and partner scope, and what EUTECNIQ does not claim.
Status. EUTECNIQ has no laboratory, equipment or data of its own yet. Every capability here is a proposal; the science is published work by others.
What the plant is, what it contains, what could be wrong.
LC-HRMS screening, molecular networks and a chemical-space map.
Route chosen on purity, recovery, solvent and cost.
Resins, cuts and blending to hold markers in range.
Carriers matched to the molecule's measured limits.
Find the step that limits exposure first.
Droplet size, stability and breakdown mechanisms.
Spray and freeze drying, glass transition, water activity.
Identity, purity, potency and contaminants against specifications.
Methods defined and validated to ICH Q2(R2).
Balances, scale-up rules and process safety.
Powder flow, scale-up rules and technology transfer.
Models labeled as models, validated against measurements.
Exposure, interactions and pharmacokinetics, up to drug rules.
| Topic (page) | 2000 | 2005 | 2010 | 2015 | 2020 | 2024 | 2025 | CAGR 2015–2025 | Search terms in title or abstract |
|---|---|---|---|---|---|---|---|---|---|
| Natural-product dereplication and structure elucidation | 10 | 31 | 24 | 72 | 130 | 151 | 221 | 11.9% | (("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") OR "natural product" OR "natural products") AND (dereplication OR "structure elucidation" OR "molecular networking") |
| Non-targeted analysis of plants | 0 | 2 | 7 | 24 | 109 | 232 | 358 | 31.0% | ("non-targeted" OR nontargeted OR untargeted) AND (metabolomics OR "high-resolution mass spectrometry" OR HRMS) AND (plant OR plants OR botanical OR herbal) |
| Advanced extraction of plants | 8 | 12 | 45 | 74 | 148 | 213 | 232 | 12.1% | ("supercritical carbon dioxide" OR "supercritical CO2" OR "pressurized liquid extraction" OR "ultrasound-assisted extraction" OR "microwave-assisted extraction") AND (plant OR plants OR herb OR herbs OR botanical OR leaves OR seeds OR roots) |
| Standardization of botanical extracts | 10 | 19 | 44 | 55 | 88 | 103 | 208 | 14.2% | ("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") AND (standardization OR standardisation OR "marker compound" OR "marker compounds") |
| Delivery systems for phytochemicals | 7 | 5 | 17 | 45 | 118 | 192 | 235 | 18.0% | (nanoemulsion OR liposome OR liposomes OR phytosome OR phytosomes OR "self-emulsifying") AND (("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") OR curcumin OR polyphenol OR polyphenols) |
| Bioavailability of phytochemicals | 46 | 62 | 176 | 279 | 624 | 946 | 1,563 | 18.8% | bioavailability AND (("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") OR polyphenol OR polyphenols OR curcumin OR flavonoid OR flavonoids) |
| Food-grade nanoemulsions | 0 | 0 | 8 | 34 | 155 | 302 | 360 | 26.6% | (nanoemulsion OR nanoemulsions OR "Pickering emulsion" OR "Ostwald ripening") AND (food OR nutraceutical OR nutraceuticals OR "essential oil" OR "essential oils") |
| Spray and freeze drying of extracts | 11 | 12 | 26 | 54 | 136 | 177 | 216 | 14.9% | ("spray drying" OR "spray-drying" OR "spray dried" OR "freeze drying" OR "freeze-drying" OR lyophilization) AND (extract OR extracts OR polyphenol OR polyphenols OR anthocyanin OR anthocyanins) |
| Chromatography and mass spectrometry of botanicals | 69 | 154 | 315 | 709 | 1,182 | 1,588 | 2,014 | 11.0% | ("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") AND ("liquid chromatography" OR HPLC OR UHPLC OR "mass spectrometry") |
| Validated methods for botanicals | 0 | 5 | 4 | 22 | 20 | 23 | 29 | 2.8% | ("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") AND ("method validation" OR "validated method" OR "ICH guidelines" OR "ICH Q2") |
| Process modeling of plant extraction | 0 | 2 | 4 | 7 | 9 | 19 | 24 | 13.1% | ("mathematical model" OR "mass transfer" OR "techno-economic" OR "process simulation") AND extraction AND (plant OR plants OR botanical OR seeds OR leaves) |
| Scale-up of botanical processes | 10 | 19 | 21 | 43 | 88 | 146 | 201 | 16.7% | ("scale-up" OR "pilot scale" OR "pilot-scale" OR "industrial scale") AND (("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") OR "dietary supplement" OR extraction) |
| Machine learning for natural products | 0 | 2 | 2 | 18 | 55 | 168 | 298 | 32.4% | ("machine learning" OR "deep learning" OR "neural network") AND (("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") OR "natural product" OR "natural products") |
| Randomized trials of botanicals | 1 | 9 | 20 | 38 | 88 | 87 | 111 | 11.3% | ("randomized controlled trial" OR "randomised controlled trial" OR "randomized clinical trial") AND ("plant extract" OR "plant extracts" OR botanical OR herbal OR phytochemical OR phytochemicals OR "medicinal plant" OR "medicinal plants") |
| Page | Labels | Verified data | Peer-reviewed | Regulation or guidance | Third-party estimate | Proposal, partner or risk | Simulation or schematic |
|---|---|---|---|---|---|---|---|
| Discovery & characterization | 34 | 14 (41%) | 9 (26%) | 3 (9%) | 0 (0%) | 6 (18%) | 2 (6%) |
| Targeted and non-targeted analysis | 24 | 8 (33%) | 3 (12%) | 0 (0%) | 0 (0%) | 2 (8%) | 11 (46%) |
| Extraction & purification | 27 | 7 (26%) | 2 (7%) | 3 (11%) | 0 (0%) | 5 (19%) | 10 (37%) |
| Purification & standardization | 28 | 1 (4%) | 7 (25%) | 1 (4%) | 0 (0%) | 6 (21%) | 13 (46%) |
| Advanced delivery | 18 | 2 (11%) | 2 (11%) | 5 (28%) | 0 (0%) | 3 (17%) | 6 (33%) |
| Bioavailability by design | 14 | 0 (0%) | 6 (43%) | 0 (0%) | 0 (0%) | 2 (14%) | 6 (43%) |
| Emulsions & colloids | 21 | 0 (0%) | 7 (33%) | 0 (0%) | 0 (0%) | 4 (19%) | 10 (48%) |
| Drying & particle engineering | 25 | 0 (0%) | 6 (24%) | 2 (8%) | 0 (0%) | 5 (20%) | 12 (48%) |
| Analytical characterization | 31 | 1 (3%) | 0 (0%) | 2 (6%) | 0 (0%) | 8 (26%) | 20 (65%) |
| Analytical method development | 22 | 2 (9%) | 0 (0%) | 4 (18%) | 0 (0%) | 5 (23%) | 11 (50%) |
| Process engineering | 53 | 5 (9%) | 2 (4%) | 2 (4%) | 0 (0%) | 13 (25%) | 31 (58%) |
| Scale-up and tech transfer | 19 | 2 (11%) | 5 (26%) | 2 (11%) | 0 (0%) | 3 (16%) | 7 (37%) |
| Computational science & AI | 24 | 5 (21%) | 3 (12%) | 0 (0%) | 0 (0%) | 10 (42%) | 6 (25%) |
| Translational research | 16 | 1 (6%) | 3 (19%) | 4 (25%) | 0 (0%) | 5 (31%) | 3 (19%) |
| Area | Planned in house | Qualified external partner |
|---|---|---|
| Discovery and characterization | Phase I Microscopy, HPTLC, HPLC, LC-MS, ICP-MS, microbiology | Partner DNA barcoding, NMR, accredited confirmatory tests |
| Extraction and purification | Phase I Laboratory extraction; Phase II pilot extraction, evaporation and solvent recovery | Partner Toll extraction at commercial scale |
| Delivery, emulsions, drying | Phase I Laboratory formulation and drying; Phase II pilot drying | Partner Human pharmacokinetic studies and bioanalysis |
| Process scale-up | Phase I Laboratory process; Phase II pilot plant; Phase III commercial manufacturing | Partner Contract manufacturers until Phase III |
| Translational and safety | Planned Exposure and literature assessment, study design, dossier writing | Partner Toxicology studies (GLP where appropriate), human studies |
"In house" means a capability planned for a proposed facility phase; "partner" means work placed with a qualified outside organization under a written agreement. No facility has been built and no partner agreement signed.
Describe the material, the target product and the question. EUTECNIQ is in formation and would respond with a proposed plan and the evidence each step would produce.